Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical stage biopharmaceutical company developing novel oncology therapeutics that primarily target cancer stem cells and tumor bulk. The company’s pipeline currently includes two clinical stage product candidates, SL-401 and SL-701. SL-401 is a targeted therapy currently being studied for the treatment of relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia. SL-701 is an immunotherapy being developed for the treatment of second-line glioblastoma multiforme. For more information, visit the company’s website at www.stemline.com.